Eli Lilly’s revenue doubled within the fourth quarter, propelled by its hot-selling diabetes and weight problems remedies, and the drugmaker got here out with a principally better-than-expected 2025 forecast.
Gross sales of Lilly’s top-selling product, the diabetes therapy Mounjaro, jumped 60% to $3.53 billion within the last quarter of 2024 whereas its weight problems therapy counterpart Zepbound introduced in $1.9 billion.
Income from the breast most cancers therapy Verzenio additionally helped, climbing 36% to $1.55 billion.
Total, Lilly’s quarterly revenue swelled to $4.41 billion. Income superior 45% to $13.53 billion, according to expectations. Per-share earnings adjusted for one-time gadgets totaled $5.32, simply topping the $5.01 that Wall Road was on the lookout for, in response to a ballot of trade analysts by FactSet.
Mounjaro and Zepbound are a part of a wave of diabetes and weight problems medicines often known as GLP-1 receptor agonists which can be hovering in reputation globally because of the quantity of weight folks lose whereas taking the injections. They compete with Ozempic and Wegovy from the Danish drugmaker Novo Nordisk, which additionally reported robust gross sales progress on Wednesday.
For 2024, Mounjaro gross sales greater than doubled to $11.54 billion, whereas Zepbound notched gross sales of $4.9 billion in its first full 12 months available on the market.
Analysts count on greater than $18 billion in gross sales from Mounjaro this 12 months and over $10 billion from Zepbound, which was lately accepted in the USA as a therapy for some types of sleep apnea.
For 2025, the Indianapolis drugmaker expects adjusted earnings to vary between $22.50 and $24 with income falling between $58 billion and $61 billion.
Analysts count on earnings of $22.77 per share on $58.8 billion in income.
Eli Lilly and Co. shares slipped 1% to $831.64 Thursday in premarket buying and selling. The inventory had already climbed 9% thus far this 12 months, as of Wednesday.